Economic Viability of New Medical Drugs in Switzerland
We are working to find economically viable prices for new medicines in Switzerland through health economics and cost-effectiveness methods.
Factsheet
- Lead school School of Health Professions
- Institute Institute of Health Economics and Health Policy
- Funding organisation Others
- Duration (planned) 01.01.2021 - 31.12.2024
- Project management Niklaus Meier
- Head of project Niklaus Meier
-
Project staff
Prof. Dr. Katharina Blankart
Niklaus Meier -
Partner
CSS Kranken-Versicherung AG
Helsana
Sanitas
SWICA Krankenversicherung AG
Situation
Switzerland faces significant challenges in the reimbursement of new medicines. The combination of rapid technological development in pharmaceuticals, lower approval barriers, and rising prices necessitates new approaches in the price negotiation of these medicines. These approaches must be capable of supporting the negotiation of economically viable prices for new medicines in a fair, consistent, and comprehensible manner based on the available evidence.
Course of action
We are developing, in collaboration with four health insurers (Helsana, Sanitas, CSS, SWICA), a value framework, the Swiss Drug Pricing Model (SDPM), for determining the prices of new medicines in Switzerland. We analyzed the methods of existing evaluation schemes based on a systematic literature review and adapted these methods for the SDPM to meet the needs of the Swiss healthcare system. We use the SDPM to determine justified prices of medicines based on their added value. A publication of the SDPM is planned.
